Health

Grant of Warrants

June 15, 2026 Announcement no. 13 Grant of Warrants Copenhagen, Denmark, June 15, 2026, (GLOBE NEWSWIRE) – The Board of…

1 week ago

Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses

MRD has scaled into a profitable, category-leading MRD diagnostics business, while Immune Medicine has built a differentiated discovery platform powered…

1 week ago

Adaptive Biotechnologies Corporation Announces Proposed Convertible Senior Notes Offering

June 15, 2026 16:05 ET  | Source: Adaptive Biotechnologies Proceeds expected to be deployed to repay the OrbiMed Purchase Agreement…

1 week ago

Intravacc and SynphaBase Announce Strategic Partnership to Advance Conjugate Vaccine Development

The companies will combine their complementary expertise in synthetic oligosaccharides, conjugation process development and GMP vaccine manufacturing to support partners…

1 week ago

2026 EHA | Over 40 Orelabrutinib Studies Presented, Including First Clinical Data from Europe and US TN CLL/SLL Patients

BEIJING, June 15, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the…

1 week ago

Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress

Poster presentations from ongoing clinical trials of two core assets, olverembatinib and lisaftoclax, highlight global innovation capabilities in hematologic malignancies…

1 week ago

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

 Achieved 100% ORR and 83.3% CR rate at dose level 2 following a single infusion in patients with relapsed/refractory B-NHL…

2 weeks ago

KFSH Highlights Human-Centered AI as a Path to Better Care at HLTH Europe 2026

RIYADH, Saudi Arabia, June 14, 2026 (GLOBE NEWSWIRE) -- At HLTH Europe 2026 in Amsterdam, taking place from June 15…

2 weeks ago

Phase 3 Data Show TransCon PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism

June 13, 2026 16:00 ET  | Source: Ascendis Pharma Multi-organ system and quality-of-life benefits sustained through three and a half…

2 weeks ago

Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026

 -- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat…

2 weeks ago